论文部分内容阅读
目的探讨普罗布考治疗糖尿病肾病的临床疗效。方法选取该院2012年10月—2013年12月收治的100例2型糖尿病肾病患者,按照入院的先后顺序,随机分为研究组和对照组,每组各50例,对照组患者给予降压、降糖等综合治疗,研究组在对照组的基础上配合普罗布考口服治疗,比较两组患者的24 h尿微量白蛋白(ALB)、血钾及肾功能情况。结果两分组患者在治疗前后,血钾及肾功能改变均无统计学意义(P>0.05);在24 h尿微量白蛋白检测的比较上,两组患者较治疗前均显著改变,研究组患者改善情况优于对照组,组间差异有统计学意义(P<0.05)。结论对于糖尿病肾病的临床治疗,临床采用普罗布考配合常规基础治疗,可有效减少患者尿微量蛋白的排泄,临床使用较为安全,可进行临床推广。
Objective To investigate the clinical efficacy of probucol in the treatment of diabetic nephropathy. Methods A total of 100 patients with type 2 diabetic nephropathy admitted from October 2012 to December 2013 in our hospital were randomly divided into study group and control group according to the order of hospital admission, 50 cases in each group. The patients in control group were given antihypertensive , Hypoglycemic and other comprehensive treatment, the study group on the basis of the control group with probucol oral treatment, two groups of patients with 24 h urine microalbumin (ALB), serum potassium and renal function. Results Before and after treatment, there was no significant difference in serum potassium and renal function between the two groups (P> 0.05); in the comparison of 24h urine microalbumin test, the two groups of patients had significant changes compared with that before treatment, and the patients in the study group The improvement was better than the control group, the difference between the groups was statistically significant (P <0.05). Conclusion For the clinical treatment of diabetic nephropathy, clinical probucol combined with conventional basic treatment, can effectively reduce the excretion of urinary microalbuminuria in patients, the clinical use of more safe and can be clinically promoted.